Postoperative delirium (POD) is a serious neurocognitive complication following major surgery, especially cardiac procedures. It presents acutely with symptoms such as disorientation, hallucinations, reduced awareness, and cognitive dysfunction. Its incidence is alarmingly high, up to 55% in cardiac surgery patients, and it is associated with poor outcomes, including prolonged hospitalization, increased mortality, and long-term cognitive decline.

In recent years, dexmedetomidine, a selective alpha-2 adrenoceptor agonist with sedative and analgesic properties, has been spotlighted as a potential prophylactic agent against POD. However, a new study published in the British Journal of Anaesthesia (Hunt et al. 2025) has called into question its efficacy and safety, particularly after a re-analysis of the largest randomized controlled trial (RCT) to date, the DECADE trial.

This post presents the findings of a comprehensive Bayesian meta-analysis and systematic review, aiming to clarify the current understanding of dexmedetomidine’s role in preventing delirium after cardiac surgery.

What the study evaluated

Primary objective: To determine whether dexmedetomidine reduces the incidence of POD in adults undergoing cardiac surgery.

Methodology:

• Design: Systematic review, Bayesian meta-analysis, and Bayesian re-analysis of the DECADE trial.
• Data: 12 RCTs involving 3,539 patients.
• Primary outcome: Incidence of POD.
• Secondary outcomes: Mortality, arrhythmias, ICU/hospital length of stay, bradycardia, hypotension, and delirium duration.

Summary of findings

1. Initial evidence favored dexmedetomidine

• Pooled odds ratio (OR): 0.67, suggesting a 33% reduction in odds of POD.
• Probability of any benefit: 99.1%.
• Probability of meeting a minimum clinically important difference (MCID): 91.0%.
  

2. Publication bias alters the conclusion

• After accounting for publication bias using Bayesian model averaging, the OR shifted to 1.15 .
• The chance of a clinically meaningful benefit dropped to 0.2%, and the probability of harm increased significantly.
  

3. Re-analysis of the DECADE trial

• Using various Bayesian priors (vague, skeptical, optimistic, neutral):
  • Most analyses still showed an increased risk of POD with dexmedetomidine.
  • Even under an optimistic prior, the chance of a clinically significant benefit was only 3.6%.
  • Using bias-adjusted meta-analytic priors: only 0.2% chance of benefit vs 76.6% chance of harm.
    

Subgroup and secondary findings

• Comparator agents matter:
  • Dexmedetomidine showed better results when compared to propofol than normal saline.
• Timing of administration:
  • Postoperative infusion was more beneficial than intraoperative or combined regimens.
• Delirium duration:
  • Reduced by an average of 0.43 days in patients receiving dexmedetomidine.

However, no consistent benefit was observed in other secondary outcomes such as mortality or ICU stay. Safety data were inconsistently reported across studies, limiting firm conclusions.

Why is there controversy?

The DECADE trial, the largest and most methodologically robust study, paradoxically found an increased risk of delirium with dexmedetomidine. This is at odds with earlier, smaller trials that reported benefit. Key reasons for conflicting results include:

• Publication bias: Studies with negative results are less likely to be published, skewing meta-analytic outcomes.
• Heterogeneity in dosing schedules, diagnostic tools, and patient populations.
• Quality of evidence: Many early randomized controlled trials (RCTs) were small or had a high risk of bias.

Clinical recommendations

For clinicians considering dexmedetomidine:

1. Evaluate patient risk factors for POD (age > 65, baseline cognitive impairment, comorbidities).
2. Review current literature. Understand that the evidence is now mixed.
3. If used, prefer postoperative dosing, particularly during nighttime.
4. Monitor hemodynamics closely to prevent bradycardia or hypotension.
5. Avoid use in low-risk patients, as the risk-benefit ratio may not be favorable.

Conclusion

The most comprehensive analysis to date reveals a more nuanced picture of dexmedetomidine’s role in preventing POD after cardiac surgery. While early studies suggested promise, the re-analysis of higher-quality data, especially the DECADE trial, shifts the balance toward caution. The impact of publication bias is particularly profound, reminding us of the importance of rigorous trial methodology and transparent reporting.

Until clearer evidence emerges, dexmedetomidine should be used judiciously and tailored to specific patient contexts, rather than as a routine preventive strategy for POD.

Reference: Hunt T et al. Perioperative dexmedetomidine for the prevention of postoperative delirium after cardiac surgery: a systematic review, Bayesian meta-analysis, and Bayesian re-analysis of the DECADE trial. Br J Anaesth. 2025;134:1671-1682. 

For more information on dexmedetomidine and its impact on perioperative care, check out Anesthesia Updates on the NYSORA Anesthesia Manual App. 

Get access to step-by-step management algorithms, the latest research, and peer-reviewed insights—all in one place. Download the app today and experience the future of anesthesia education and decision-making.

AI On Call: Case of the Week

A 72-year-old man is scheduled for elective aortic valve replacement. He has a history of atrial fibrillation and well-controlled diabetes.

What measures can be taken to prevent postoperative delirium in this patient?